Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team - Company reports strong growth.
• Finance expert Pascal Schmidt joins the management team as of August 1, 2018
• Growth trajectory maintained with 84% increase in revenues in 2017
• Significant progression in the development of the Carragelose® and Marinosolv® platforms in 2017
(firmenpresse) -
Vienna, July 31, 2018. Vienna based Marinomed Biotech AG (Marinomed) strengthens its management team with the appointment of Pascal Schmidt as Chief Financial Officer (CFO) from August 1, 2018. This addition to the leadership team marks another important milestone in the further growth trajectory of the biopharmaceutical firm which develops innovative technology platforms.
Pascal Schmidt, 45 years old, holds a degree in business administration from the University of Bayreuth and has more than 20 years&A. Most recently, he held the position of managing director at Raymond James Financial Inc. Prior to this role, he was a partner at consultancy firm Mummert & Company and a member of the Investment Committee at Infineon Ventures.
Chair of the Supervisory Board Simon Nebel comments:
Strong performance by the company across all segments in 2017
Marinomed
Next to its pipeline with various innovative products in development, Marinomed has already been generating revenues from the sale of its existing Carragelosets business activities, with cash and cash equivalents in the amount of EUR 6.0 million as of 31 December 2017 (2016: EUR 2.0 million).
According to Dr Andreas Grassauer, CEO and co-founder of Marinomed, the trend in earnings and company performance marks a major step forward for the company: s of Marinosolv
Solid business development expected for 2018
Marinomed expects its business development to continue positively in 2018. management board at Marinomed. Marinomed expects further substantial growth potential in the pharmaceutical market for OTC products. The company is aiming to forge additional partnerships and access new markets to maximize this potential.
Overview of key figures
according to IFRS in Mio. EUR20172016
Revenues4.8 2.6
EBIT-1.6 -1.5
Cash and cash equivalents (as of 31 December)6.0 2.0
Employees (as of 31 December)2726
About Marinomed Biotech AG
Marinomed is a Vienna based biopharmaceutical company focusing on the development of innovative products in the field of respiratory and ophthalmological diseases based on its IP protected technology platforms.
The platform Carragelose
Marinosolv
Further information is available at www.marinomed.com and www.carragelose.com.
Enquiries:
Contact
Dr Eva Prieschl-Grassauer
Chief Scientific Officer
Veterin
1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl(at)marinomed.com
http://www.marinomed.com
Contact
Roland Mayrl
Managing Partner
Prinz-Eugen-Stra
1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl(at)metrum.at
http://www.metrum.at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.07.2018 - 05:59 Uhr
Sprache: Deutsch
News-ID 1539152
Anzahl Zeichen: 5927
contact information:
Contact person: TCJ
Town:
Wien
Phone: 01 505 70 44
Kategorie:
Drugs
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 31.07.2018
Anmerkungen:
Diese Pressemitteilung wurde bisher 1630 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team - Company reports strong growth.
"
steht unter der journalistisch-redaktionellen Verantwortung von
PRD (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
